3-amino-N-(3-imidazol-1-yl-propyl)-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-amino-N-(3-imidazol-1-yl-propyl)-benzamide
• 英文别名: 3-Amino-N-[3-(1H-imidazol-1-yl)propyl]benzamide；3-amino-N-(3-imidazol-1-ylpropyl)benzamide
• 化学式: C₁₃H₁₆N₄O
• mdl: MFCD11195963
• 分子量: 244.296
• InChiKey: BGEYMLDXNXVCOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  72.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-amino-N-(3-imidazol-1-yl-propyl)-benzamide 、 (E)-3-(4-(adamantan-1-yl)phenoxy)acrylic acid 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以23.2%的产率得到(E)-3-[3-(4-adamantan-1-yl-phenoxy)-acryloylamino]-N-(3-imidazole-1-yl-propyl)-benzamide
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationship of (E)-Phenoxyacrylic Amide Derivatives as Hypoxia-Inducible Factor (HIF) 1α Inhibitors

  摘要：

  A series of (E)-phenoxyacrylic amide derivatives were synthesized and evaluated as hypoxia inducible factor (HIF) la inhibitors. The present structure activity relationship study on this series identified the morpholinoethyl containing ester 4p as a potent inhibitor of HIF-1 alpha under hypoxic conditions (IC50 = 0.12 mu M in a cell-based HRE reporter assay) in HCT116 cells. The representative compound 4p suppressed hypoxia-induced HIF-1 alpha accumulation and targeted gene expression in a dose-dependent manner. The effect of HIF-l alpha inhibition by 4p was further demonstrated by its inhibitory activity on in vitro tube formation and migration of cells, which may be valuable for development of novel therapeutics for cancer and tumor angiogenesis.

  DOI：

  10.1021/jm301419d
• 作为产物：
  描述：

  1-(3-氨基丙基)咪唑 在 5%-palladium/activated carbon 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 生成 3-amino-N-(3-imidazol-1-yl-propyl)-benzamide
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationship of (E)-Phenoxyacrylic Amide Derivatives as Hypoxia-Inducible Factor (HIF) 1α Inhibitors

  摘要：

  A series of (E)-phenoxyacrylic amide derivatives were synthesized and evaluated as hypoxia inducible factor (HIF) la inhibitors. The present structure activity relationship study on this series identified the morpholinoethyl containing ester 4p as a potent inhibitor of HIF-1 alpha under hypoxic conditions (IC50 = 0.12 mu M in a cell-based HRE reporter assay) in HCT116 cells. The representative compound 4p suppressed hypoxia-induced HIF-1 alpha accumulation and targeted gene expression in a dose-dependent manner. The effect of HIF-l alpha inhibition by 4p was further demonstrated by its inhibitory activity on in vitro tube formation and migration of cells, which may be valuable for development of novel therapeutics for cancer and tumor angiogenesis.

  DOI：

  10.1021/jm301419d

文献信息

• N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical
  申请人：American Cyanamid Company

  公开号：US04568687A1

  公开（公告）日：1986-02-04

  This disclosure describes novel N-[.omega.-(1H-imidazol-1-yl)alkyl]arylamides which possess the property of inhibiting the enzyme thromboxane synthetase and are also useful in the treatment of hypertension and myocardial ischemia.

  这份披露描述了一种新颖的N-[.omega.-(1H-咪唑-1-基)烷基]芳基酰胺，具有抑制血栓素合酶酶活性的特性，并且在治疗高血压和心肌缺血方面也很有用。
• ARYLOXY PHENOXY ACRYLIC COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT
  申请人：Lee Kyeong

  公开号：US20130237542A1

  公开（公告）日：2013-09-12

  The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

  本发明涉及一种抑制HF-1活性的化合物，以及该化合物的制备方法和包含该化合物作为活性成分的药物组合物。本发明的化合物通过抑制HIF-1活性而不是通过非选择性细胞毒性表现出抗癌活性，HIF-1是在癌细胞生长和转移中起重要作用的转录因子。因此，根据本发明的化合物或其药用盐抑制HIF-1活性，因此可以用作固体肿瘤如结肠癌、肝癌、胃癌和乳腺癌的治疗剂。此外，根据本发明的化合物或其药用盐还可以用作糖尿病视网膜病变或关节炎的治疗剂的活性成分，当HIF-1诱导的VEGF表达增加时，这些疾病可能会恶化。
• N-(2-4-(1H-imidazol-1-yl)alkyl)arylamides
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0117462A2

  公开（公告）日：1984-09-05

  This disclosure describes novel N-[ω-(1H-imidazol-1-yl)alkyl]arylamides which possess the property of inhibiting the enzyme thromboxane synthetase and are also useful in the treatment of hypertension and myocardial ischemia.

  本公开介绍了新型 N-[ω-(1H-咪唑-1-基)烷基]芳基酰胺，它们具有抑制血栓素合成酶的特性，还可用于治疗高血压和心肌缺血。
• US4568687A
  申请人：——

  公开号：US4568687A

  公开（公告）日：1986-02-04
• US8940936B2
  申请人：——

  公开号：US8940936B2

  公开（公告）日：2015-01-27